Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (375)	1/6/1999 9:29:00 AM
From: Ian@SI	Read Replies (2) \| Respond to of 1321

Ed, I certainly didn't mean to leave any impression that I was praising ML for its foresight. Far from it... For whatever reason, they seem to be in love with Miravant. In the latest QLT upgrade, they acknowledged that Miravant hasn't even got its phase III trial started nor is there any definite date by which it will be. A nice article in today's Nationalpost / Financial Post pegging the drug's market at about $800M USD / Annum. I suspect that $45 / share targets will be easily exceeded before we get our NDA from the FDA this year. This is one chick that I think can be reasonably counted before it's completely hatched. FWIW, Ian.